Jennifer is the first HLA-mismatched patient in the world to successfully receive a kidney transplant where transplantation tolerance was actively induced. She has now lived more than 15 years without having to take any anti-rejection immunosuppression. Take a look at this short video of how ITBMed’s therapy changed her life.
The life-long immunosuppression associated with transplantation negatively impacts patients’ health and the transplanted organ itself. With the therapy developed at ITBMed it has been proven that patients can live a life completely without immunosuppression, leading to improved quality of life and reduced health care costs. Listen to Professor David Sachs explain the clinical problems facing the field of transplantation, and how ITBMed’s lead candidate TCD601 (siplizumab) can help improve the lives of transplant patients.
The path of Siplizumab
After 20 years of research at Harvard University and Massachusetts General Hospital we are at the doorstep of transforming transplantation of solid organs. Siplizumab is an anti-CD2 monoclonal antibody specifically targeting an immune pathway leading to a combination of unique effects which makes it ideal in the treatment of transplant patients.